Overview

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Erlotinib Hydrochloride